AP1891A - HIV immunogenic compositions and methods. - Google Patents
HIV immunogenic compositions and methods.Info
- Publication number
- AP1891A AP1891A APAP/P/2001/002300A AP2001002300A AP1891A AP 1891 A AP1891 A AP 1891A AP 2001002300 A AP2001002300 A AP 2001002300A AP 1891 A AP1891 A AP 1891A
- Authority
- AP
- ARIPO
- Prior art keywords
- mammal
- immunogenic compositions
- hiv
- iss
- adjuvant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides immunogenic compositions which enhance ?-chemokine levels in a mammal. The immunogenic compositions contain an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The HIV antigen can be a whole-killed HIV virus devoid of outer envelope protein gp120. Alternatively, the HIV antigen can be a whole-killed HIV virus, or a p24 antigen. Also provided are kits, the components of which, when combined, produce the immunogenic compositions of the invention. The invention also provides methods of making the immunogenic compositions, by combining an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. The invention further provides a method of immunizing a mammal, by enhancing b-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant. Also provided is a method of inhibiting aids, by enhancing ?-chemokine production in the mammal by administering to the mammal an immunogenic composition containing an HIV antigen, an isolated nucleic acid molecule containing an immunostimulatory sequence (ISS) and an adjuvant.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13276299P | 1999-05-06 | 1999-05-06 | |
US15066799P | 1999-08-25 | 1999-08-25 | |
PCT/US2000/012495 WO2000067787A2 (en) | 1999-05-06 | 2000-05-05 | Hiv immunogenic compositions and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
AP2001002300A0 AP2001002300A0 (en) | 2001-12-31 |
AP1891A true AP1891A (en) | 2008-09-23 |
Family
ID=26830710
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/2001/002300A AP1891A (en) | 1999-05-06 | 2000-05-05 | HIV immunogenic compositions and methods. |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1176978A2 (en) |
AP (1) | AP1891A (en) |
AU (1) | AU4992900A (en) |
BR (1) | BR0010323A (en) |
CA (1) | CA2372960C (en) |
CR (1) | CR6491A (en) |
OA (1) | OA11937A (en) |
WO (1) | WO2000067787A2 (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
ES2628744T3 (en) | 1998-05-22 | 2017-08-03 | Ottawa Hospital Research Institute | Methods and products to induce immunity in mucous membranes |
JP2003523721A (en) | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | Polynucleotides encoding antigenic HIVC-type polypeptides, polypeptides, and uses thereof |
US7776343B1 (en) | 1999-02-17 | 2010-08-17 | Csl Limited | Immunogenic complexes and methods relating thereto |
ES2250151T3 (en) * | 1999-06-29 | 2006-04-16 | Glaxosmithkline Biologicals S.A. | USE OF CPG AS A VACCINE ASSISTANT AGAINST HIV. |
JP4188687B2 (en) | 2000-12-27 | 2008-11-26 | ダイナバックス テクノロジーズ コーポレイション | Immunomodulating polynucleotides and methods of use thereof |
CA2435568A1 (en) * | 2001-01-26 | 2002-08-01 | The Immune Response Corporation | Method for treating an hiv-infected individual by combining immunization with structured interruption of anti-retroviral treatment |
US8114418B2 (en) | 2001-06-21 | 2012-02-14 | Dynavax Technologies Corporation | Chimeric immunomodulatory compounds and methods of using the same—IV |
CA2634992C (en) | 2001-07-05 | 2012-10-16 | Novartis Vaccines And Diagnostics, Inc. | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
NZ552377A (en) | 2001-08-17 | 2008-08-29 | Coley Pharm Gmbh | Combination motif immune stimulatory oligonucleotides with improved activity |
AR045702A1 (en) | 2001-10-03 | 2005-11-09 | Chiron Corp | COMPOSITIONS OF ASSISTANTS. |
CA2388049A1 (en) | 2002-05-30 | 2003-11-30 | Immunotech S.A. | Immunostimulatory oligonucleotides and uses thereof |
US20040053880A1 (en) | 2002-07-03 | 2004-03-18 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
CA2494508A1 (en) * | 2002-07-03 | 2004-01-15 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
US7807803B2 (en) | 2002-07-03 | 2010-10-05 | Coley Pharmaceutical Group, Inc. | Nucleic acid compositions for stimulating immune responses |
ES2381224T3 (en) | 2002-10-29 | 2012-05-24 | Coley Pharmaceutical Group, Inc. | Use of CPG oligonucleotides in the treatment of hepatitis C virus infection |
JP2006512927A (en) | 2002-12-11 | 2006-04-20 | コーリー ファーマシューティカル グループ,インコーポレイテッド | 5 'CPG nucleic acids and methods of use thereof |
US8158768B2 (en) | 2002-12-23 | 2012-04-17 | Dynavax Technologies Corporation | Immunostimulatory sequence oligonucleotides and methods of using the same |
ES2381309T3 (en) | 2002-12-23 | 2012-05-25 | Dynavax Technologies Corporation | Sequence of immunostimulatory oligonucleotides and methods for using them |
WO2005021726A2 (en) * | 2003-08-28 | 2005-03-10 | The Immune Response Corporation | Immunogenic hiv compositions and related methods |
MY159370A (en) | 2004-10-20 | 2016-12-30 | Coley Pharm Group Inc | Semi-soft-class immunostimulatory oligonucleotides |
MX2009003398A (en) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity. |
WO2010051820A1 (en) * | 2008-11-10 | 2010-05-14 | Aarhus Universitet | Multiplexed cytokine vaccination |
JP6059220B2 (en) | 2011-07-06 | 2017-01-18 | ノバルティス アーゲー | Oil-in-water emulsion containing nucleic acid |
CA2840965C (en) | 2011-07-06 | 2021-03-02 | Novartis Ag | Cationic oil-in-water emulsions |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998055495A2 (en) * | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5087758B2 (en) * | 1997-03-10 | 2012-12-05 | オタワ ホスピタル リサーチ インスティチュート | Use of nucleic acids containing unmethylated CpG dinucleotides as adjuvants |
-
2000
- 2000-05-05 EP EP00932163A patent/EP1176978A2/en not_active Withdrawn
- 2000-05-05 OA OA1200100291A patent/OA11937A/en unknown
- 2000-05-05 BR BR0010323-3A patent/BR0010323A/en not_active IP Right Cessation
- 2000-05-05 CA CA002372960A patent/CA2372960C/en not_active Expired - Fee Related
- 2000-05-05 AU AU49929/00A patent/AU4992900A/en not_active Abandoned
- 2000-05-05 AP APAP/P/2001/002300A patent/AP1891A/en active
- 2000-05-05 WO PCT/US2000/012495 patent/WO2000067787A2/en active Application Filing
-
2001
- 2001-10-25 CR CR6491A patent/CR6491A/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998055495A2 (en) * | 1997-06-06 | 1998-12-10 | Dynavax Technologies Corporation | Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof |
Non-Patent Citations (2)
Title |
---|
Vaccine, GB, Butterworth Scientific, Guildford, Vol. 16, No. 7, 1 * |
Vaccine, Vol. 18, No. 11-12, 01/2000 * |
Also Published As
Publication number | Publication date |
---|---|
CA2372960C (en) | 2006-03-28 |
WO2000067787A3 (en) | 2001-04-26 |
EP1176978A2 (en) | 2002-02-06 |
CR6491A (en) | 2005-05-31 |
CA2372960A1 (en) | 2000-11-16 |
BR0010323A (en) | 2002-01-08 |
AP2001002300A0 (en) | 2001-12-31 |
WO2000067787A2 (en) | 2000-11-16 |
OA11937A (en) | 2006-04-12 |
AU4992900A (en) | 2000-11-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AP1891A (en) | HIV immunogenic compositions and methods. | |
ES2272012T5 (en) | FUSION PROTEINS THAT INCLUDE TAT AND / OR NEF PROTEINS OF HIV-1. | |
MXPA01011047A (en) | Neisseria genomic sequences and methods of their use. | |
MY129263A (en) | Vaccine composition | |
MY136081A (en) | Modified hiv - 1gag p17 peptide and immunogenic composition | |
HK1044484B (en) | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide | |
TW200621806A (en) | Vaccine | |
EP1373301A4 (en) | Reducing the immunogenicity of fusion proteins | |
MXPA01003557A (en) | Neisseria genomic sequences and methods of their use. | |
DK1104306T3 (en) | Preparations of CpG and Saponin Adjuvants and Methods for Using Them | |
HK1038507A1 (en) | Influenza virus vaccine composition | |
ZA200500073B (en) | Iscom preparation and use thereof. | |
MXPA04001224A (en) | Agents for enhancing the immune response. | |
MX349481B (en) | Novel immunogenic compositions for the prevention and treatment of meningococcal disease. | |
WO2004007679A3 (en) | Dendritic cell pontentiation | |
NO20091665L (en) | Tumor-associated antigen derivatives from the MAGE family, and the nucleic acid sequences encoding them, used for the preparation of fusion proteins and for vaccine compositions | |
NZ525752A (en) | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV | |
WO2003082183A3 (en) | Protein-based streptococcus pneumoniae vaccines | |
WO2005013918A3 (en) | Compositions, methods and kits relating to poxvirus subunit vaccines | |
AU2457100A (en) | Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs | |
WO2002036790A3 (en) | Influenza virus vector for infection of dendritic cells | |
YU24004A (en) | Interleukin-12 as a veterinary vaccine adjuvant | |
MA32821B1 (en) | VACCINE COMBINALLY COMBINED AGAINST COQUELUCHE (WHOLE CELLULAR VACCINE) | |
WO2005021726A3 (en) | Immunogenic hiv compositions and related methods | |
EP0830456A4 (en) | ISOLATED FrpB NUCLEIC ACID MOLECULE AND VACCINE |